Status:
COMPLETED
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
Abbott
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiv...
Detailed Description
Study M03-658 was a continuation study for participants with moderate to severe psoriasis who had participated in a prior psoriasis adalimumab study. Study M03-658 consisted of three sequential treatm...
Eligibility Criteria
Inclusion
- Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
- Subjects who met the requirements from previous adalimumab psoriasis study participation.
Exclusion
- Subject considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
- Female subject who was pregnant or breast-feeding or considering becoming pregnant.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
1469 Patients enrolled
Trial Details
Trial ID
NCT00195676
Start Date
May 1 2004
End Date
October 1 2009
Last Update
April 13 2011
Active Locations (104)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 1263
Birmingham, Alabama, United States, 35205
2
Site Reference ID/Investigator# 1259
Buckner 13075 PI, Alabama, United States, 35233
3
Site Reference ID/Investigator# 2427
Scottsdale, Arizona, United States, 85251
4
Site Reference ID/Investigator# 2433
Tucson, Arizona, United States, 85710